ReShape Lifesciences™ is America's premier weight loss and metabolic health-solutions company, offering an integrated portfolio of proven products and services that manage and treat obesity and metabolic disease. The FDA-approved Lap-Band® Program provides minimally invasive, long-term treatment of obesity and is an alternative to more invasive surgical stapling procedures such as the gastric bypass or sleeve gastrectomy. The ReShape Vest™ System is an investigational (outside the U.S.) minimally invasive, laparoscopically implanted medical device that wraps around the stomach, emulating the gastric volume reduction effect of conventional weight-loss surgery. It helps enable rapid weight loss in obese and morbidly obese patients without permanently changing patient anatomy. reshapecare™ is a virtual weight-management program that supports lifestyle changes for all weight-loss patients led by board certified health coaches to help them keep the weight off over time. The recently launched ReShape Marketplace™ is an online collection of quality wellness products curated for all consumers to help them achieve their health goals.
Company profile
Ticker
RSLS
Exchange
Website
CEO
Andrew Rasdal
Employees
Incorporated
Location
Fiscal year end
Industry (SIC)
Baxter International • Boston Scientific • Stryker • Becton, Dickinson And • 3M • Teleflex • Resmed • Haemonetics • Hill-Rom • Nuvasive ...
Former names
OBALON THERAPEUTICS INC
SEC CIK
Corporate docs
Subsidiaries
ReShape Weightloss, Inc. • ReShape Lifesciences Netherlands B.V. • ReShape Lifesciences Australia Pty Ltd • ReShape Costa Rica Sociedad de Responsabilidad Limited • Obalon Center for Weight Loss, Inc. ...
RSLS stock data
Latest filings (excl ownership)
424B4
Prospectus supplement with pricing info
8 Feb 23
EFFECT
Notice of effectiveness
6 Feb 23
S-1MEF
Registration of additional securities for an S-1
3 Feb 23
S-1/A
IPO registration (amended)
3 Feb 23
RW WD
Withdrawal of registration withdrawal request
2 Feb 23
RW
Registration withdrawal request
2 Feb 23
RW
Registration withdrawal request
2 Feb 23
S-1/A
IPO registration (amended)
1 Feb 23
8-K
Other Events
27 Jan 23
S-1/A
IPO registration (amended)
26 Jan 23
Transcripts
RSLS
Earnings call transcript
2022 Q3
14 Nov 22
RSLS
Earnings call transcript
2022 Q2
16 Aug 22
RSLS
Earnings call transcript
2019 Q4
29 Feb 20
RSLS
Earnings call transcript
2019 Q3
8 Nov 19
RSLS
Earnings call transcript
2019 Q2
24 Jul 19
RSLS
Earnings call transcript
2018 Q4
22 Feb 19
RSLS
Earnings call transcript
2018 Q3
2 Nov 18
RSLS
Earnings call transcript
2018 Q2
4 Aug 18
RSLS
Earnings call transcript
2018 Q1
12 May 18
RSLS
Earnings call transcript
2017 Q4
6 Mar 18
Latest ownership filings
Financial summary
| Quarter (USD) | Sep 22 | Jun 22 | Mar 22 | Dec 21 | |
|---|---|---|---|---|---|
| Revenue | |||||
| Cost of revenue | |||||
| Operating income | |||||
| Operating margin | |||||
| Net income | |||||
| Net profit margin | |||||
| Cash on hand | |||||
| Change in cash | |||||
| Diluted EPS |
| Annual (USD) | Dec 21 | Dec 20 | Dec 19 | Dec 18 | |
|---|---|---|---|---|---|
| Revenue | |||||
| Cost of revenue | |||||
| Operating income | |||||
| Operating margin | |||||
| Net income | |||||
| Net profit margin | |||||
| Cash on hand | |||||
| Change in cash | |||||
| Diluted EPS |
| Cash burn rate (est.) | Burn method: Change in cash | Burn method: Operating income | Burn method: FCF (opex + capex) | Last Q | Avg 4Q | Last Q | Avg 4Q | Last Q | Avg 4Q |
|---|---|---|---|---|---|---|
| Cash on hand (at last report) | 6.25 mm | 6.25 mm | 6.25 mm | 6.25 mm | 6.25 mm | 6.25 mm |
| Cash burn (monthly) | 1.77 mm | 1.92 mm | 4.06 mm | 5.48 mm | 1.76 mm | 1.87 mm |
| Cash used (since last report) | 7.68 mm | 8.35 mm | 17.65 mm | 23.83 mm | 7.64 mm | 8.16 mm |
| Cash remaining | -1.44 mm | -2.11 mm | -11.41 mm | -17.58 mm | -1.40 mm | -1.91 mm |
| Runway (months of cash) | -0.8 | -1.1 | -2.8 | -3.2 | -0.8 | -1.0 |
Institutional ownership, Q2 2022
| 13F holders | Current |
|---|---|
| Total holders | 21 |
| Opened positions | 5 |
| Closed positions | 3 |
| Increased positions | 4 |
| Reduced positions | 3 |
| 13F shares | Current |
|---|---|
| Total value | 755.00 k |
| Total shares | 1.36 mm |
| Total puts | 0.00 |
| Total calls | 0.00 |
| Total put/call ratio | – |
| Largest owners | Shares | Value |
|---|---|---|
| Vanguard | 503.62 k | $290.00 k |
| Geode Capital Management | 297.86 k | $171.00 k |
| T. Rowe Price | 170.90 k | $99.00 k |
| Armistice Capital | 142.99 k | $82.00 k |
| Domain Parters Vii L P | 62.50 k | $0.00 |
| Renaissance Technologies | 44.70 k | $26.00 k |
| NTRS Northern Trust | 33.43 k | $19.00 k |
| Virtu Financial | 25.58 k | $15.00 k |
| Citadel Advisors | 21.55 k | $12.00 k |
| STT State Street | 20.70 k | $12.00 k |
Recent insider trades
| Date | Owner | Security | Transaction | Code | Indirect | 10b5-1 | $Price | #Shares | $Value | #Remaining |
|---|---|---|---|---|---|---|---|---|---|---|
| 1 Dec 22 | Thomas Stankovich | Common Stock, $0.001 par value per share | Sell | Dispose S | No | No | 0.1509 | 2,213 | 333.94 | 325,404 |
| 1 Dec 22 | Thomas Stankovich | Common Stock, $0.001 par value per share | Sell | Dispose S | No | No | 0.1513 | 5,144 | 778.29 | 327,617 |
| 28 Nov 22 | Thomas Stankovich | Common Stock, $0.001 par value per share | Sell | Dispose S | No | No | 0.1695 | 364,756 | 61.83 k | 332,761 |
| 17 Nov 22 | Thomas Stankovich | Common Stock, $0.001 par value per share | Grant | Acquire A | No | No | 0 | 364,756 | 0.00 | 697,517 |
| 4 Nov 22 | Thomas Stankovich | Common Stock, $0.001 par value per share | Sell | Dispose S | No | No | 0.2724 | 2,510 | 683.72 | 332,761 |
| 4 Nov 22 | Thomas Stankovich | Common Stock, $0.001 par value per share | Sell | Dispose S | No | No | 0.2725 | 5,883 | 1.60 k | 335,271 |
| 4 Oct 22 | Thomas Stankovich | Common Stock, $0.001 par value per share | Sell | Dispose S | No | No | 0.2812 | 2,484 | 698.50 | 338,670 |
| 4 Oct 22 | Thomas Stankovich | Common Stock, $0.001 par value per share | Sell | Dispose S | No | No | 0.2807 | 5,809 | 1.63 k | 341,154 |
| 6 Sep 22 | Thomas Stankovich | Common Stock, $0.001 par value per share | Sell | Dispose S | No | No | 0.39 | 4,828 | 1.88 k | 346,963 |
News
12 Health Care Stocks Moving In Wednesday's Intraday Session
8 Feb 23
ReShape Lifesciences Announces Closing of Upsized $10.2M Underwritten Public Offering; Shares Spike Higher
8 Feb 23
Nasdaq Down Over 100 Points; Tyson Foods Posts Downbeat Earnings
6 Feb 23
Why Omeros Are Trading Higher By 32%? Here Are Other Stocks Moving In Monday's Mid-Day Session
6 Feb 23
Crude Oil Down Over 1%; Nasdaq Drops 80 Points
6 Feb 23
Press releases
ReShape Lifesciences Announces Closing of Upsized $10.2 Million Underwritten Public Offering
8 Feb 23
ReShape Lifesciences Announces Pricing of Upsized $10.2 Million Underwritten Public Offering
6 Feb 23
Thinking about buying stock in ReShape Lifesciences, Exicure, Blue Apron, Coherus Biosciences, or Icecure Medical?
23 Dec 22
ReShape Lifesciences Announces 1-for-50 Reverse Stock Split Effective as of Commencement of Trading on December 23, 2022
22 Dec 22
ReShape Lifesciences™ Reports Third Quarter 2022 Financial Results and Provides Corporate Update
14 Nov 22